Investors hero

Investors

DURECT Overview

DURECT is a late-stage biopharmaceutical company pioneering the development of epigenetic therapies that target dysregulated DNA methylation to transform the treatment of serious and life-threatening conditions, including acute organ injury and cancer. Our unique approach has the potential to make meaningful improvements in patients’ lives and transform human medicine. Larsucosterol, DURECT’s lead drug candidate, binds to and inhibits the activity of DNA methyltransferases (DNMTs), epigenetic enzymes that are elevated and associated with hypermethylation found in patients with alcohol-associated hepatitis (AH). We are evaluating larsucosterol for the potential treatment of AH, for which FDA has granted a Fast Track Designation. In addition, POSIMIR® (bupivacaine solution) for infiltration use, a non-opioid analgesic utilizing the innovative SABER® platform technology, is FDA-approved and has been exclusively licensed to Innocoll Pharmaceuticals for commercialization in the United States.

Investor Relations Contact

Contact: Ashley R. Robinson

LifeSci Advisors

arr@lifesciadvisors.com

Email Alerts Sign-Up

Scroll to Top